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 Implication for health policy/practice/research/medical education:
Total ghrelin and acylated ghrelin (AG) levels seems unaffected by GH status in children. Amino acids are unable to blunt ghrelin 
secretion irrespective of GH status. Ghrelin secretion seems to be partially refractory to somatostatin action. 
1. Background 
Ghrelin is a 28 amino acid peptide. Although predomi-
nantly produced by the stomach, it is also produced by 
several other tissues, including the pituitary and hypo-
thalamus (1-3). It is the first discovered natural ligand of 
the orphan growth hormone (GH) secretagogues recep-
tor type 1a (GHS-R1a) and induces a strong GH-releasing 
activity on activation (1, 4-6). Ghrelin circulates in the 
Background: The physiological link between ghrelin and growth hormone (GH) has not yet 
been fully clarified. Furthermore, the existence of a negative feedback mechanism between 
growth hormone–insulin-like growth factor (GH–IGF)-I axis and ghrelin and the influence of 
amino acids on ghrelin secretion in children remain matters of debate.
Objectives: To understand the regulation of ghrelin secretion and clarify the relationship 
between ghrelin and GH secretion in GH-deficient (GHD) and GH-sufficient (GHS) children 
Patients and Methods: Ten GHD (male/female [M/F], 6/4; age [mean ± SEM], 10.7 ± 0.9 years) 
and 10 GHS prepubertal children (M/F, 6/4; age [mean ± SEM], 10.3 ± 0.6 years), underwent an 
arginine (ARG) test (infusion, 0.5 g/kg, iv). Levels of GH, total ghrelin, and acylated ghrelin 
(AG) were assayed every 30 min from 0 to +120 min.
Results: Peak GH values were lower in GHD subjects than in GHS subjects (P < 0.0001). The 
baseline levels, peak levels, or area under the curves (AUC) for total ghrelin and AG were 
similar between GHD and GHS children. ARG infusion was followed by a slight to significant 
decrease in total ghrelin levels, but not AG levels, both in GHD and GHS subjects with a na-
dir at +30 min. No correlation was seen between GH, total ghrelin, or AG response and ARG 
infusion. 
Conclusions: Total ghrelin and AG levels seemed unaffected by GH status in prepubertal chil-
dren. ARG infusion was unable to blunt ghrelin secretion irrespective of GH status in child-
hood. Moreover, since ARG influences GH secretion via modulation of somatostatin release, 
ghrelin secretion seems to be partially refractory to somatostatin action. 
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blood in 2 different forms. Acylated ghrelin (AG) contains 
an acyl group bound to the octanoyl group on a serine-3 
residue of the molecule; acylation at serine-3 is essential 
for GHS-R1a activation (1, 5) Unacylated ghrelin (UAG) is 
the commonly present circulating form and it has a lot of 
physiological functions (7-9). Circulating ghrelin levels 
are mainly influenced by the nutritional and metabolic 
statuses of an individual, and the levels increase with 
fasting and energy restriction and decrease with food 
intake, glucose metabolism, and insulin secretion (10-12).
GH secretion from the pituitary gland is regulated by 
the coordinated action of GH-releasing hormone (GHRH) 
and somatostatin (SRIH), which, respectively, stimulate 
and inhibit the release of GH  (13, 14). GH secretion is also 
influenced by metabolic and hormonal signals from oth-
er glands, including release of glucocorticoids, thyroid 
hormones, and sex steroids, which may act directly or 
via hypothalamic connections. Furthermore, GH regu-
lates its own secretion by a feedback mechanism. Other 
peripheral mediators, such as insulin-like growth factor 
I (IGF-I), free fatty acids, glucose, and insulin, can act as a 
part of this feedback mechanism (15).
The GH-releasing effect of ghrelin is mediated by GHRH-
secreting neurons at the hypothalamic level. Ghrelin and 
GHRH have synergic activities indicating that they act, at 
least partially, by different mechanisms of action (16, 17). 
Nevertheless, ghrelin needs GHRH activity to fully exert 
the GH-releasing effect. Since ghrelin mainly acts at the 
hypothalamic level, it requires the integrity of hypotha-
lamic-pituitary connections (18, 19). Furthermore, ghre-
lin is an antagonist of SRIH at both the hypothalamic and 
pituitary levels (3, 20). 
Despite the stimulatory effect of acute ghrelin adminis-
tration on GH secretion, the physiological link between 
ghrelin and GH has not yet been clarified (21, 22). The fol-
lowing conflicting results have been obtained in clinical 
studies: (a) existence of a relationship between GH and 
circulating ghrelin levels (23), (b) absence of a relation-
ship between GH and ghrelin levels (24), and (c) existence 
of a relationship between GH and ghrelin levels under 
specific conditions such as fasting or the time of day (25).
Furthermore, many studies have been conducted in 
short-statured children and adults to assess the existence 
of a negative feedback mechanism between the GH–IGF-I 
axis and ghrelin by using different GH provocative tests; 
however, the results remain controversial (26-30). 
2. Objectives
We studied total ghrelin and AG secretion with re-
spect to GH response in a classical GH-stimulation test 
in GH-deficient (GHD) and GH-sufficient (GHS) chil-
dren. The aims of this study were to understand the 
regulation of ghrelin secretion and the relationship 
between ghrelin and GH secretion in a better way and 
to clarify the influence of amino acids on ghrelin se-
cretion in children.
3. Patients and Methods
Between November 2008 and June 2010, 20 short-stat-
ured children, admitted to the Division of Pediatrics, Uni-
versity of Eastern Piedmont, Novara, Italy, were enrolled 
in this study. Informed parental consent and approval by 
the local ethical committee were obtained before begin-
ning the study. 
Inclusion criterion was a short stature, which was de-
fined as height with a standard deviation (SD) score be-
low -2 on Italian growth charts (31). Exclusion criterion 
was the presence of a known cause of short stature, such 
as hypothyroidism, chronic diseases, or celiac disease; 
small for gestational age children were excluded.
On the basis of cut-off levels of GH response to classi-
cal stimulation tests for the diagnosis of GH deficiency 
(peak GH level, < 10 ng/mL) in children (32), we classi-
fied 10 patients as GHD and 10 as GHS. The subjects un-
derwent a complete clinical examination, and auxo-
logical parameters were evaluated according to Italian 
growth charts (31). Height and weight were, respectively, 
measured by using the Harpenden stadiometer and an 
electronic scale. Body mass index (BMI) was calculated 
as body weight divided by squared height (kg/m2), and 
BMI SD score was assessed using the least mean square 
method (LMS method) (31). Brain magnetic resonance 
imaging (MRI) was performed for all GHD children and 
the condition was classified as idiopathic GH deficiency. 
The median follow-up time for the assessment of growth 
velocity and other auxological parameters was 6 months.
All subjects underwent an arginine test (ARG) (infusion, 
0.5 g/kg, iv, maximum 30 g, within 30 min) from 8:00 to 
8:30 AM, after overnight fasting. An intravenous catheter 
was placed in the antecubital vein half an hour prior to 
the test. Blood was sampled at baseline and 30, 60, 90, 
and 120 min after ARG infusion. Serum GH and ghrelin 
level were measured at each test point (33), while IGF-I 
concentration was measured only at the baseline. 
For serum preparations, GH and IGF-I were collected in 
tubes containing no anticoagulants while total ghrelin 
and AG were directly drawn into tubes containing potas-
sium ethylenediaminetetraacetic acid (K2EDTA). AG plas-
ma samples were centrifugated (15 min, 3000 rpm, 4°C), 
acidified with HCl (1 M), and pretreated with a protease 
inhibitor cocktail. The samples were stored at -80°C.   
All samples were analyzed within 15 days from the day 
of collection.
Plasma GH, IGF-I, AG, and total ghrelin levels were meas-
ured using commercially available kits. 
 During provocative tests, GH levels were measured us-
ing a chemiluminescent immunoassay system (IMMU-
LITE 2000, Siemens); serum IGF-I levels were measured 
using LIASION automated chemiluminescence analyzer, 
supplied by DiaSorin, with a measurement range of 
3–1,500 ng/mL. To determine the immunoreactive ghre-
lin concentration, total ghrelin levels (pg/mL) in plasma 
were assayed in duplicate by using a commercially avail-
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able radioimmunoassay (RIA) (Phoenix Pharmaceuticals, 
Mountain View, CA, USA) following the manufacturer’s 
recommendations. Intra- and inter-assay coefficients of 
variation (CV) were below 5.3% and 13.6%, respectively. 
Plasma AG levels (pg/mL) were measured in duplicate us-
ing a commercial RIA kit (LINCO Research Inc, Millipore, 
MO, USA) following the manufacturer’s recommenda-
tions. The antibody showed 100% cross-reactivity to hu-
man AG and <0.1% cross-reactivity to unacylated human 
ghrelin. Intra- and inter-assay CV values were below 13.9% 
and 20.4%, respectively. Data were expressed as mean ± 
SEM. Area under the curves (AUC) was calculated using 
trapezoidal integration.  A sample size of 10 individu-
als from each group was required to provide sufficient 
power (80%) to detect a difference of 50 pg/mL with SD of 
40 pg/mL at a significance level of 95% between the mean 
ghrelin levels in the 2 groups (34). For continuous varia-
bles, the variation between the groups was compared us-
ing nonparametric Wilcoxon and Mann–Whitney U tests, 
as appropriate. A correlation analysis was performed us-
ing the Spearman’s correlation test. A p value of < 0.05 
was considered statistically significant. All statistical 
analyses were performed using SPSS for Windows ver-
sion 15.0 (SPSS INC; Chicago, IL, USA). 
4. Results
Gender distribution and the mean age were  similar 
between GHD and GHS children.  All patients were pre-
pubertal or in early puberty (Tanner pubertal stages I or 
II). All clinical and hormonal data are shown in Table 1. 
The peak GH values were significantly lower in GHD chil-
dren (mean: 6.1 ng/mL, range: 3.9–8.4 ng/mL) than in GHS 
children (mean: 22.0 ng/mL, range: 12.1–62.3 ng/mL; P < 
0.0001). IGF-I levels in GHD children (mean: 179.8 ng/mL, 
range: 27.0–399.0 ng/mL) were not statistically different 
from those in GHS children (mean: 250.9 ng/mL, range: 
114.0–600.0 ng/mL) (Figure 1).
The baseline total ghrelin levels were similar between 
the 2 groups (GHS: mean, 327.7 pg/mL; range, 98.0–706.0 
pg/mL; GHD: mean, 270.3 pg/mL; range, 50.2–519.6 pg/
mL). Furthermore, the peak total ghrelin levels in the 
GHD b GHS b
Case , No. 10 10
Gender (M/F) a 6/4 6/4
Age, y 10.7 ± 0.9 10.3 ± 0.6
Height, cm 128.6 ± 4.7 128.8 ± 3.6
Height, SDS a -2.0 ± 0.1 -1.7 ± 0.1
Weight, kg 33.8 ± 4.5 24.7 ± 1.7
BMI a, kg/m 2 18.7 ± 2.2 15.2 ± 0.5
IGF-I level, ng/mL 179.8 ± 49.6 250.9 ± 50.4
IGF-I level, SDS  a -0.4 ± 0.2 0.2 ± 0.2
Baseline GH level, ng/mL 1.5 ± 0.8 2.9 ± 1.2
Peak GH level, ng/mL 6.1 ± 0.4 c 22.0 ± 4.7 c
AUC a GH, ng/mL×h 5.2 ± 0.8 c 22.4 ± 4.7 c
Baseline TG a level, pg/mL 270.3 ± 49.8 327.7 ± 58.3
Peak TG a level, pg/mL 392.9 ± 88.7 461.1 ± 69.7
AUC a TG a, pg/mL×h 554.7 ± 114.6 649.9 ± 109.7
Baseline AG a level, pg/mL 40.6 ± 8.4 41.6 ± 5.5
Peak AG a level, pg/mL 52.6 ± 7.0 73.6 ± 16.3
AUC a AG a, pg/mL×h 74.4 ± 7.7 90.4 ± 14.3
Table 1. Clinical and Hormonal Response to Arginine in GHD and GHS 
Children
a Abbreviations: AG, Acylated ghrelin; AUC, Area under the curve; BMI, 
Body mass index; F, Female; H, Hour; M, Male; Sds, Standard deviation 
score; Tg, Total ghrelin; Ghs, Growth hormone sufficient; GHD, Growth 
hormone deficient
b Data are expressed as Mean ± SEM
c P < 0.0001
Figure 1. Mean ± SEM Values of Serum GH, Total Ghrelin, and Acylated 
Ghrelin (AG) during the Arginine Test in GH-Deficient (GHD) and GH-Suf-
ficient (GHS) Children
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GHS children (mean: 461.1 pg/mL, range: 127.0–841.0 pg/
mL) were not significantly different from those in GHD 
children (mean: 392.9 pg/mL; range: 153.0–1029.0 pg/mL). 
The AUC for total ghrelin levels was also similar for the 
2 groups (GHS: mean, 649.9 pg/mL·h; range, 177.8–1365.9 
pg/mL·h; GHD: mean, 554.7 pg/mL·h; range, 210.9–1359.6 
pg/mL·h) (Figure 1).
The baseline AG levels were similar between the 2 
groups (GHS: mean, 41.6 pg/mL; range, 27.9–74.4 pg/mL; 
GHD: mean, 40.6 pg/mL; range, 17.7–112.1 pg/mL). Further-
more, the peak AG levels in the GHS children (mean: 73.6 
pg/mL, range: 25.5–201.1 pg/mL) were not significantly dif-
ferent from those in GHD children (mean: 52.6 pg/mL, 
range: 19.5–86.1 pg/mL). The AUC for AG levels was also 
similar for the 2 groups (GHS: mean, 90.4 pg/mL·h; range, 
47.5–189.7 pg/mL·h; GHD: mean, 74.4 pg/mL·h; range, 
38.9–105.4 pg/mL·h (Figure 1). 
ARG infusion was followed by a slight to significant 
decrease in total ghrelin levels, but not AG levels both in 
GHD and GHS subjects, with a nadir at +30 min; however, 
the results were not statistically significant. No correla-
tion was seen between GH response and total ghrelin 
and AG levels. 
5. Discussion
This study evaluated the response of total ghrelin and 
AG level to a classical GH stimulation test in GHD and 
GHS children. Total ghrelin and AG levels were not modu-
lated on acute ARG infusion irrespective of the GH status. 
The lack of modulation of total ghrelin secretion is con-
sistent with the findings of previous studies in which 
ARG alone or glucagon was administered in both chil-
dren and adults with GHD and/or GHS (26, 35, 36). Inter-
estingly, despite the remarkable effect of significant vari-
ation in circulating ghrelin levels on insulin, glucose, 
and GH levels, amino acids coupling was not observed. 
This finding is of particular interest taking into account 
that no effect was recorded after continuous infusion 
of ARG instead of acute bolus or oral loads, despite the 
effect of insulin and glucose levels associated with con-
tinuous infusion being stronger (35, 36). Moreover, since 
ARG affects GH secretion via modulation of SRIH release, 
ghrelin secretion seems to be partially refractory to SRIH 
action, which is also observed in adults (35). However, a 
recent study showed inhibition of ghrelin secretion after 
administration of GHRH and ARG in GHD and GHS adults. 
This decrease in ghrelin levels cannot be attributed to 
GH release induced by ARG (35, 36) and might be a result 
of an inhibitory effect exerted by GHRH (30). Oral cloni-
dine administration has been reported to blunt ghrelin 
secretion in GHS children, although a delayed increase 
in ghrelin secretion was observed in GHD children (29). 
This effect of oral clonidine might be related to its direct 
gastric action since it is known to play a role in delaying 
gastric emptying, inhibiting gastric motility, and to a 
major extent, in all gastric secretion (37). Regulation of 
ghrelin secretion by clonidine or other molecules with 
respect to GH status suggests specific actions of some 
molecules, as observed on dexamethasone administra-
tion, and needs further evaluation (28). 
The role of the GH status with respect to ghrelin secre-
tion is still a matter of debate. Janssen et al. reported that 
GHD adults had similar ghrelin levels as those seen in 
controls and that a 1-year GH replacement therapy failed 
to modulate circulating ghrelin levels. The lack of modu-
lation of ghrelin secretion with respect to baseline levels 
after a relatively prolonged GH therapy was hypothesized 
to be a consequence of a balance between reduction of 
adiposity and insulin resistance and increased circulat-
ing GH levels (38). Similarly, in some studies, ghrelin lev-
els were similar in GHD and GHS children and adults at 
fasting (28, 39-43). These findings are consistent with our 
results that suggest that ghrelin does not modulate the 
quantity but mainly quality of GH secretion by modulat-
ing the GH pulse amplitude (40). In contrast, Giavioli et 
al. showed lower ghrelin levels in GHD adults, which in-
creased after a long-term treatment with recombinant 
human growth hormone (rhGH) possibly because of 
modifications of body fat stores rather than of GH–IGF-I 
levels (40). These findings are also in contrast with those 
of Engstrom who recorded a decrease in total ghrelin 
levels after 9 months of rhGH treatment in GHD subjects 
(42). These discordant data may be attributed to patients’ 
selection, group size, dose of rhGH treatments, and other 
comorbidities and need to be investigated further.
Similarly, in our study, AG levels were not modulated 
by ARG infusion. To our knowledge, this is the first study 
that aimed to evaluate AG secretion with respect to ami-
no acid regulation. A recent study failed to show modula-
tion of AG with respect to GH status in humans (44).
In conclusion, this study shows that there is no correla-
tion between GH and total ghrelin levels and AG levels in 
prepubertal GHD and GHS children at fasting or during 
a classical GH-provocative test. ARG infusion could not 
blunt ghrelin secretion irrespective of the GH status in 
childhood. Moreover, since ARG influences GH secretion 
via modulation of SRIH release, ghrelin secretion seems 
to be partially refractory to SRIH action.
Reference
1. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough 
P, et al. The tissue distribution of the mRNA of ghrelin and sub-
types of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 
2002;87(6):2988.
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 
Ghrelin is a growth-hormone-releasing acylated peptide from 
stomach. Nature. 1999;402(6762):656-60.
3. Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo 
E. Neuroendocrine and peripheral activities of ghrelin: implica-
tions in metabolism and obesity. Eur J Pharmacol. 2002;440(2-
3):235-54.
4. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, 
Rosenblum CI, et al. A receptor in pituitary and hypothala-
mus that functions in growth hormone release. Science. 
1996;273(5277):974-7.
5. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol 
474 Int J Endocrinol Metab. 2012;10(2)
Prodam F et al. Ghrelin in GH Sufficient and GH Deficient Children
Rev. 2005;85(2):495-522.
6. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physi-
ological, pathophysiological, and pharmacological aspects of 
ghrelin. Endocr Rev. 2004;25(3):426-57.
7. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, et 
al. Non-acylated ghrelin counteracts the metabolic but not the 
neuroendocrine response to acylated ghrelin in humans. J Clin 
Endocrinol Metab. 2004;89(6):3062-5.
8. Gauna C, Delhanty PJ, Hofland LJ, Janssen JA, Broglio F, Ross RJ, 
et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, 
glucose output by primary hepatocytes. J Clin Endocrinol Metab. 
2005;90(2):1055-60.
9. Gil-Campos M, Aguilera CM, Canete R, Gil A. Ghrelin: a hor-
mone regulating food intake and energy homeostasis. Br J Nutr. 
2006;96(2):201-26.
10. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, et 
al. Stomach is a major source of circulating ghrelin, and feeding 
state determines plasma ghrelin-like immunoreactivity levels 
in humans. J Clin Endocrinol Metab. 2001;86(10):4753-8.
11. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, 
Weigle DS. A preprandial rise in plasma ghrelin levels suggests a 
role in meal initiation in humans. Diabetes. 2001;50(8):1714-9.
12. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, 
et al. Plasma ghrelin levels in lean and obese humans and the 
effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 
2002;87(1):240-4.
13. Hartman ML, Faria AC, Vance ML, Johnson ML, Thorner MO, Veld-
huis JD. Temporal structure of in vivo growth hormone secre-
tory events in humans. Am J Physiol. 1991;260(1 Pt 1):E101-10.
14. Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML. 
Growth hormone-releasing hormone and growth hormone-
releasing peptide as therapeutic agents to enhance growth 
hormone secretion in disease and aging. Recent Prog Horm Res. 
1997;52:215-44; discussion 44-6.
15. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of 
growth hormone secretion. Physiol Rev. 1999;79(2):511-607.
16. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, et 
al. Endocrine activities of ghrelin, a natural growth hormone 
secretagogue (GHS), in humans: comparison and interactions 
with hexarelin, a nonnatural peptidyl GHS, and GH-releasing 
hormone. J Clin Endocrinol Metab. 2001;86(3):1169-74.
17. Hataya Y, Akamizu T, Takaya K, Kanamoto N, Ariyasu H, Saijo M, 
et al. A low dose of ghrelin stimulates growth hormone (GH) 
release synergistically with GH-releasing hormone in humans. 
J Clin Endocrinol Metab. 2001;86(9):4552.
18. Maghnie M, Pennati MC, Civardi E, Di Iorgi N, Aimaretti G, Foschini 
ML, et al. GH response to ghrelin in subjects with congenital GH 
deficiency: evidence that ghrelin action requires hypothalamic-
pituitary connections. Eur J Endocrinol. 2007;156(4):449-54.
19. Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, et 
al. Ghrelin main action on the regulation of growth hormone 
release is exerted at hypothalamic level. J Clin Endocrinol Metab. 
2003;88(7):3450-3.
20. Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship 
between the novel peptide ghrelin and somatostatin/growth 
hormone-releasing hormone in regulation of pulsatile growth 
hormone secretion. Endocrinology. 2003;144(3):967-74.
21. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Hara-
da M, et al. Ghrelin strongly stimulates growth hormone release 
in humans. J Clin Endocrinol Metab. 2000;85(12):4908-11.
22. Tolle V, Bassant MH, Zizzari P, Poindessous-Jazat F, Tomasetto C, 
Epelbaum J, et al. Ultradian rhythmicity of ghrelin secretion in 
relation with GH, feeding behavior, and sleep-wake patterns in 
rats. Endocrinology. 2002;143(4):1353-61.
23. Koutkia P, Canavan B, Breu J, Johnson ML, Grinspoon SK. Noc-
turnal ghrelin pulsatility and response to growth hormone 
secretagogues in healthy men. Am J Physiol Endocrinol Metab. 
2004;287(3):E506-12.
24. Avram AM, Jaffe CA, Symons KV, Barkan AL. Endogenous circulat-
ing ghrelin does not mediate growth hormone rhythmicity or 
response to fasting. J Clin Endocrinol Metab. 2005;90(5):2982-7.
25. Muller AF, Lamberts SW, Janssen JA, Hofland LJ, Koetsveld PV, 
Bidlingmaier M, et al. Ghrelin drives GH secretion during fast-
ing in man. Eur J Endocrinol. 2002;146(2):203-7.
26. Hirsh D, Heinrichs C, Leenders B, Wong AC, Cummings DE, 
Chanoine JP. Ghrelin is suppressed by glucagon and does not 
mediate glucagon-related growth hormone release. Horm Res. 
2005;63(3):111-8.
27. Matsuoka H, Hosoda H, Sugawara H, Iwama S, Kim HS, Kanga-
wa K, et al. Short-term secretory regulation of ghrelin during 
growth hormone provocative tests in prepubertal children 
with various growth hormone secretory capacities. Horm Res. 
2005;64(6):274-9.
28. Radetti G, Prodam F, Lauriola S, Di Dio G, D’Addato G, Corneli 
G, et al. Acute ghrelin response to intravenous dexamethasone 
administration in idiopathic short stature or isolated idio-
pathic growth hormone-deficient children. J Endocrinol Invest. 
2008;31(3):224-8.
29. Stylianou C, Galli-Tsinopoulou A, Grammatikopoulou MG, Ko-
liakos G, Varlamis G. Ghrelin and growth hormone serum levels 
during the clonidine test in children with short stature and vari-
able growth hormone status. Hormones (Athens). 2011;10(1):39-
45.
30. Tarantini B, Ciuoli C, Checchi S, Montanaro A, Bonato V, Theodo-
ropoulou A, et al. Serum ghrelin levels in growth hormone-suf-
ficient and growth hormone-deficient patients during growth 
hormone-releasing hormone plus arginine test. J Endocrinol In-
vest. 2009;32(4):335-7.
31. Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, et al. 
Italian cross-sectional growth charts for height, weight and BMI 
(2 to 20 yr). J Endocrinol Invest. 2006;29(7):581-93.
32. Richmond EJ, Rogol AD. Growth hormone deficiency in chil-
dren. Pituitary. 2008;11(2):115-20.
33. Groschl M, Wagner R, Dotsch J, Rascher W, Rauh M. Preana-
lytical influences on the measurement of ghrelin. Clin Chem. 
2002;48(7):1114-6.
34. Holistic Numerical Methods. Transforming Numerical Methods 
Education for the STEM Undergraduate. 2012 [updated 2011 Jan]; 
Available from: http://numericalmethods.eng.usf.edu/topics/
trapezoidal_rule.htm.
35. Broglio F, Gottero C, Prodam F, Destefanis S, Gauna C, Me E, et 
al. Ghrelin secretion is inhibited by glucose load and insulin-in-
duced hypoglycaemia but unaffected by glucagon and arginine 
in humans. Clin Endocrinol (Oxf). 2004;61(4):503-9.
36. Prodam F, Me E, Riganti F, Gramaglia E, Bellone S, Baldelli 
R, et al. The nutritional control of ghrelin secretion in hu-
mans: the effects of enteral vs. parenteral nutrition. Eur J Nutr. 
2006;45(7):399-405.
37. Ramkumar D, Schulze KS. Gastroduodenal motility. Curr Opin 
Gastroenterol. 2003;19(6):540-5.
38. Janssen JA, van der Toorn FM, Hofland LJ, van Koetsveld P, Broglio 
F, Ghigo E, et al. Systemic ghrelin levels in subjects with growth 
hormone deficiency are not modified by one year of growth hor-
mone replacement therapy. Eur J Endocrinol. 2001;145(6):711-6.
39. Eden Engstrom B, Burman P, Holdstock C, Karlsson FA. Effects 
of growth hormone (GH) on ghrelin, leptin, and adiponectin in 
GH-deficient patients. J Clin Endocrinol Metab. 2003;88(11):5193-8.
40. Giavoli C, Cappiello V, Corbetta S, Ronchi CL, Morpurgo PS, Fer-
rante E, et al. Different effects of short- and long-term recombi-
nant hGH administration on ghrelin and adiponectin levels in 
GH-deficient adults. Clin Endocrinol (Oxf). 2004;61(1):81-7.
41. Jarkovska Z, Rosicka M, Marek J, Hana V, Weiss V, Justova V, et 
al. Plasma levels of total and active ghrelin in acromegaly and 
growth hormone deficiency. Physiol Res. 2006;55(2):175-81.
42. Jung CH, Lee WY, Rhee EJ, Kim SY, Oh KW, Yun EJ, et al. Serum 
ghrelin and leptin levels in adult growth hormone deficiency 
syndrome. Arch Med Res. 2006;37(5):612-8.
43. Ryber L, Obrink K, Houe N, Frystyk J, Jorgensen JO. Serum ghre-
lin levels are suppressed in hypopituitary patients following 
insulin-induced hypoglycaemia irrespective of GH status. Clin 
Endocrinol (Oxf). 2006;65(2):210-4.
44. Kim SW, Kim KW, Shin CS, Park do J, Park KS, Cho BY, et al. Acylated 
ghrelin secretion is acutely suppressed by oral glucose load or 
insulin-induced hypoglycemia independently of basal growth 
hormone secretion in humans. Horm Res. 2007;67(5):211-9.
